This study proposes a series of clinical and related preclinical investigations to minimize peritransplant tumor burden and to reduce the chances of post-transplantation recurrence of certain lymphomas and of other cancers. Autologous IL-2 activated natural killer cells have been shown to fill a broad spectrum of tumor targets. Thus, autologous lymphocytes may have anti-tumor activity which may be most effective in a minimal residual disease setting indeced by autologous transplantation. In this study, we will test the safety and tolerance of subcutaneous, low dose IL-2 +/- GM-CSF on an outpatient basis in subjects who have had an autologous transplant for lymphoma, breast cancer, chronic myelogenous leukemia, or multiple myeloma.
Showing the most recent 10 out of 724 publications
